Overview

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
Phase:
Phase 3
Details
Lead Sponsor:
Cumberland Pharmaceuticals
Theravance Biopharma Antibiotics, Inc.
Treatments:
Methicillin
Telavancin
Vancomycin